Specification
| Target | CD70 |
| Clone | Cusatuzumab |
| Isotype | Human IgG1(E356D/M358L)-Lambda2 |
| Expression System | CHO |
| Purification | Protein A |
| Recommended Isotope Control | |
| Recommended Dilution Buffer | PBS, pH 7.62 |
| Formulation | PBS, pH 7.4,Contains no stabilizers or preservatives |
| Endotoxin | <1EU/mg Determined by LAL gel clotting assay |
| Purity | >95% Determined by SDS-PAGE |
| Sterility | 0.2 μM filtered |
| Storage | This antibody can be storaged at 2°C to 8 °C for 2 weeks under sterile conditions;-20°C for 3 months under sterile conditions;-70°C for 36 months under sterile conditions.Avoid repeated freeze-thaw. |
| Disclaim | For Research Use Only |
Background
| Background | CD70 is a ligand expressed on the surface of activated lymphocytes and mature dendritic cells that, in its binding to CD27 receptors, plays an important role in cell proliferation and survival. An overexpression of CD70 can result in the proliferation of malignant cells and has been documented in a variety of solid and hematological malignancies.2 Cusatuzumab is a humanized IgG1 antibody targeted against CD70.1 It is currently being investigated in the Phase 2 CULMINATE trial, in combination with azacitidine, for the treatment of newly-diagnosed acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS) in patients unsuitable for chemotherapy. |
QC Data
| Note | Please contact us for QC Data |
| Product Image (Reference Only) |  |